Targeting TGF-β Signaling in Cancer

Trends in Cancer

Volumn 3, Issue 1, 2017, Pages 56-71

  Colak, Selcuk ^a   ten Dijke, Peter ^a,b,c  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UPPSALA UNIVERSITY   (Sweden)

^c UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

cancer; microenvironment; TGF ; therapy resistance; tumor initiating cells

Indexed keywords

BIOLOGICAL MARKER; SMAD PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TUMOR MARKER;

CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RESISTANCE; HUMAN; NONHUMAN; PERSONALIZED MEDICINE; PRIORITY JOURNAL; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; STROMA CELL; TUMOR CELL; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG RESISTANCE; METABOLISM; NEOPLASM;

ANIMALS; BIOMARKERS, TUMOR; DRUG RESISTANCE, NEOPLASM; HUMANS; NEOPLASMS; PRECISION MEDICINE; SIGNAL TRANSDUCTION; SMAD PROTEINS; TRANSFORMING GROWTH FACTOR BETA;

EID: 85008659764     PISSN: 24058033     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trecan.2016.11.008     Document Type: Review

References (116)

1. 1 Massague, J., TGFβ in cancer. Cell 134 (2008), 215–230.
2. 2 Guinney, J., et al. The consensus molecular subtypes of colorectal cancer. Nat. Med. 21 (2015), 1350–1356.
3. 3 Calon, A., et al. Stromal gene expression defines poor-prognosis subtypes in colorectal cancer. Nat. Genet. 47 (2015), 320–329.
4. 4 Nieto, M.A., et al. EMT: 2016. Cell 166 (2016), 21–45.
5. 5 Beerling, E., et al. Plasticity between epithelial and mesenchymal states unlinks EMT from metastasis-enhancing stem cell capacity. Cell Rep. 14 (2016), 2281–2288.
6. 6 Fischer, K.R., et al. Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance. Nature 527 (2015), 472–476.
7. 7 Zheng, X., et al. Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer. Nature 527 (2015), 525–530.
8. 8 Akalay, I., et al. Epithelial-to-mesenchymal transition and autophagy induction in breast carcinoma promote escape from T-cell-mediated lysis. Cancer Res. 73 (2013), 2418–2427.
9. 9 Drabsch, Y., ten Dijke, P., TGF-β signalling and its role in cancer progression and metastasis. Cancer Metastasis Rev. 31 (2012), 553–568.
10. 10 Akhurst, R.J., Derynck, R., TGF-β signaling in cancer – a double-edged sword. Trends Cell Biol. 11 (2001), S44–S51.
11. 11 Akhurst, R.J., Hata, A., Targeting the TGFβ signalling pathway in disease. Nat. Rev. Drug Discov. 11 (2012), 790–811.
12. 12 Herbertz, S., et al. Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-β signaling pathway. Drug Des. Devel. Ther. 9 (2015), 4479–4499.
13. 13 Heldin, C.H., Moustakas, A., Role of Smads in TGFβ signaling. Cell Tissue Res. 347 (2012), 21–36.
14. 14 Schmierer, B., Hill, C.S., TGFβ-SMAD signal transduction: molecular specificity and functional flexibility. Nat. Rev. Mol. Cell Biol. 8 (2007), 970–982.
15. 15 Flanders, K.C., Wakefield, L.M., Transforming growth factor-βs and mammary gland involution; functional roles and implications for cancer progression. J. Mammary Gland Biol. Neoplasia 14 (2009), 131–144.
16. 16 Robertson, I.B., Rifkin, D.B., Regulation of the bioavailability of TGF-β and TGF-β-related proteins. Cold Spring Harb. Perspect. Biol., 2016 Published online June 1, 2016 http://dx.doi.org/10.1101/cshperspect.a021907.
17. 17 Mu, Y., et al. Non-Smad signaling pathways. Cell Tissue Res. 347 (2012), 11–20.
18. 18 Lee, M.K., et al. TGF-β activates Erk MAP kinase signalling through direct phosphorylation of ShcA. EMBO J. 26 (2007), 3957–3967.
19. 19 Massague, J., TGFβ signalling in context. Nat. Rev. Mol. Cell Biol. 13 (2012), 616–630.
20. 20 Akhurst, R.J., Padgett, R.W., Matters of context guide future research in TGFβ superfamily signaling. Sci. Signal., 8, 2015, re10.
21. 21 Luo, K., Signaling cross talk between TGF-β/Smad and other signaling pathways. Cold Spring Harb. Perspect. Biol., 2016 Published online November 11, 2016 http://dx.doi.org/10.1101/cshperspect.a022137.
22. 22 Rodon, L., et al. Active CREB1 promotes a malignant TGFβ2 autocrine loop in glioblastoma. Cancer Discov. 4 (2014), 1230–1241.
23. 23 Wakefield, L.M., Hill, C.S., Beyond TGFβ: roles of other TGFβ superfamily members in cancer. Nat. Rev. Cancer 13 (2013), 328–341.
24. 24 Fearon, E.R., Molecular genetics of colorectal cancer. Annu. Rev. Pathol. 6 (2011), 479–507.
25. 25 de Miranda, N.F., et al. Transforming growth factor β signaling in colorectal cancer cells with microsatellite instability despite biallelic mutations in TGFBR2. Gastroenterology 148 (2015), 1427–1437.
26. 26 Yakicier, M.C., et al. Smad2 and Smad4 gene mutations in hepatocellular carcinoma. Oncogene 18 (1999), 4879–4883.
27. 27 Riggins, G.J., et al. Frequency of Smad gene mutations in human cancers. Cancer Res. 57 (1997), 2578–2580.
28. 28 David, C.J., et al. TGF-β tumor suppression through a lethal EMT. Cell 164 (2016), 1015–1030.
29. 29 Gryfe, R., et al. Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. N. Engl. J. Med. 342 (2000), 69–77.
30. 30 Moustakas, A., Heldin, C.H., Mechanisms of TGFβ-induced epithelial–mesenchymal transition. J. Clin. Med., 5, 2016, 63.
31. 31 Chen, W.J., ten Dijke, P., Immunoregulation by members of the TGFβ superfamily. Nat. Rev. Immunol. 16 (2016), 723–740.
32. 32 Flavell, R.A., et al. The polarization of immune cells in the tumour environment by TGFβ. Nat. Rev. Immunol. 10 (2010), 554–567.
33. 33 Rouce, R.H., et al. The TGF-β/SMAD pathway is an important mechanism for NK cell immune evasion in childhood B-acute lymphoblastic leukemia. Leukemia 30 (2016), 800–811.
34. 34 Nam, J.S., et al. Transforming growth factor β subverts the immune system into directly promoting tumor growth through interleukin-17. Cancer Res. 68 (2008), 3915–3923.
35. 35 Vanpouille-Box, C., et al. TGFβ is a master regulator of radiation therapy-induced antitumor immunity. Cancer Res. 75 (2015), 2232–2242.
36. 36 Kim, B.G., et al. Smad4 signalling in T cells is required for suppression of gastrointestinal cancer. Nature 441 (2006), 1015–1019.
37. 37 Howe, J.R., et al. Mutations in the SMAD4/DPC4 gene in juvenile polyposis. Science 280 (1998), 1086–1088.
38. 38 Shenoy, S., Genetic risks and familial associations of small bowel carcinoma. World J. Gastrointest. Oncol. 8 (2016), 509–519.
39. 39 Principe, D.R., et al. Loss of TGFβ signaling promotes colon cancer progression and tumor-associated inflammation. Oncotarget., 2016 Published online June 4, 2016 http://dx.doi.org/10.18632/oncotarget.9830.
40. 40 Pardali, E., et al. Signaling by members of the TGF-β family in vascular morphogenesis and disease. Trends Cell Biol. 20 (2010), 556–567.
41. 41 de Vinuesa, A.G., et al. Targeting tumour vasculature by inhibiting activin receptor-like kinase (ALK)1 function. Biochem. Soc. Trans. 44 (2016), 1142–1149.
42. 42 Paauwe, M., et al. Endoglin for tumor imaging and targeted cancer therapy. Expert Opin. Ther. Targets 17 (2013), 421–435.
43. 43 Bhowmick, N.A., et al. TGF-β signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia. Science 303 (2004), 848–851.
44. 44 Cheng, N., et al. Loss of TGF-β type II receptor in fibroblasts promotes mammary carcinoma growth and invasion through upregulation of TGF-α-, MSP- and HGF-mediated signaling networks. Oncogene 24 (2005), 5053–5068.
45. 45 Cheng, N., et al. Enhanced hepatocyte growth factor signaling by type II transforming growth factor-β receptor knockout fibroblasts promotes mammary tumorigenesis. Cancer Res. 67 (2007), 4869–4877.
46. 46 Malanchi, I., et al. Interactions between cancer stem cells and their niche govern metastatic colonization. Nature 481 (2012), 85–89.
47. 47 De Sousa, F., Melo, E., et al. Poor-prognosis colon cancer is defined by a molecularly distinct subtype and develops from serrated precursor lesions. Nat. Med. 19 (2013), 614–618.
48. 48 Calon, A., et al. Dependency of colorectal cancer on a TGF-β-driven program in stromal cells for metastasis initiation. Cancer Cell 22 (2012), 571–584.
49. 49 Masur, S.K., et al. Myofibroblasts differentiate from fibroblasts when plated at low density. Proc. Natl. Acad. Sci. U. S. A. 93 (1996), 4219–4223.
50. 50 Mishra, P.J., et al. Carcinoma-associated fibroblast-like differentiation of human mesenchymal stem cells. Cancer Res. 68 (2008), 4331–4339.
51. 51 De Wever, O., et al. Stromal myofibroblasts are drivers of invasive cancer growth. Int. J. Cancer 123 (2008), 2229–2238.
52. 52 Barcellos-de-Souza, P., et al. Mesenchymal stem cells are recruited and activated into carcinoma-associated fibroblasts by prostate cancer microenvironment-derived TGF-β1. Stem. Cells 34 (2016), 2536–2547.
53. 53 Quante, M., et al. Bone marrow-derived myofibroblasts contribute to the mesenchymal stem cell niche and promote tumor growth. Cancer Cell 19 (2011), 257–272.
54. 54 Zeisberg, E.M., et al. Discovery of endothelial to mesenchymal transition as a source for carcinoma-associated fibroblasts. Cancer Res. 67 (2007), 10123–10128.
55. 55 Pallangyo, C.K., et al. IKKβ acts as a tumor suppressor in cancer-associated fibroblasts during intestinal tumorigenesis. J. Exp. Med. 212 (2015), 2253–2266.
56. 56 Koliaraki, V., et al. IKKβ in intestinal mesenchymal cells promotes initiation of colitis-associated cancer. J. Exp. Med. 212 (2015), 2235–2251.
57. 57 Korpal, M., et al. Imaging transforming growth factor-β signaling dynamics and therapeutic response in breast cancer bone metastasis. Nat. Med. 15 (2009), 960–966.
58. 58 Garrison, K., et al. The small molecule TGF-β signaling inhibitor SM16 synergizes with agonistic OX40 antibody to suppress established mammary tumors and reduce spontaneous metastasis. Cancer Immunol. Immunother. 61 (2012), 511–521.
59. 59 Maier, A., et al. Anti-tumor activity of the TGF-β receptor kinase inhibitor galunisertib (LY2157299 monohydrate) in patient-derived tumor xenografts. Cell Oncol. 38 (2015), 131–144.
60. 60 Ostapoff, K.T., et al. Neutralizing murine TGFβR2 promotes a differentiated tumor cell phenotype and inhibits pancreatic cancer metastasis. Cancer Res. 74 (2014), 4996–5007.
61. −/− transgenic model of melanoma. J. Clin. Oncol., 32(Suppl), 2014, A3011.
62. 62 Zhong, Z., et al. Anti-transforming growth factor β receptor II antibody has therapeutic efficacy against primary tumor growth and metastasis through multieffects on cancer, stroma, and immune cells. Clin. Cancer Res. 16 (2010), 1191–1205.
63. 63 Yang, Y.A., et al. Lifetime exposure to a soluble TGF-β antagonist protects mice against metastasis without adverse side effects. J. Clin. Invest. 109 (2002), 1607–1615.
64. 64 Hau, P., et al. Inhibition of TGF-β2 with AP 12009 in recurrent malignant gliomas: from preclinical to phase I/II studies. Oligonucleotides 17 (2007), 201–212.
65. 65 Bogdahn, U., et al. Targeted therapy for high-grade glioma with the TGF-β2 inhibitor trabedersen: results of a randomized and controlled phase IIb study. Neuro. Oncol. 13 (2011), 132–142.
66. 66 Giaccone, G., et al. A phase III study of belagenpumatucel-L, an allogeneic tumour cell vaccine, as maintenance therapy for non-small cell lung cancer. Eur. J. Cancer 51 (2015), 2321–2329.
67. 67 Morris, J.C., et al. Phase I study of GC1008 (fresolimumab): a human anti-transforming growth factor-β (TGFβ) monoclonal antibody in patients with advanced malignant melanoma or renal cell carcinoma. PLoS One, 9, 2014, e90353.
68. 68 Anderton, M.J., et al. Induction of heart valve lesions by small-molecule ALK5 inhibitors. Toxicol. Pathol. 39 (2011), 916–924.
69. 69 Gueorguieva, I., et al. Defining a therapeutic window for the novel TGF-β inhibitor LY2157299 monohydrate based on a pharmacokinetic/pharmacodynamic model. Br. J. Clin. Pharmacol. 77 (2014), 796–807.
70. 70 Kovacs, R.J., et al. Cardiac safety of TGF-β receptor I kinase inhibitor LY2157299 monohydrate in cancer patients in a first-in-human dose study. Cardiovasc. Toxicol. 15 (2015), 309–323.
71. 71 Rodon, J., et al. Pharmacokinetic, pharmacodynamic and biomarker evaluation of transforming growth factor-β receptor I kinase inhibitor, galunisertib, in phase 1 study in patients with advanced cancer. Invest. New Drugs 33 (2015), 357–370.
72. 72 Rodon, J., et al. First-in-human dose study of the novel transforming growth factor-β receptor I kinase inhibitor LY2157299 monohydrate in patients with advanced cancer and glioma. Clin. Cancer Res. 21 (2015), 553–560.
73. 73 Parsons, D.W., et al. An integrated genomic analysis of human glioblastoma multiforme. Science 321 (2008), 1807–1812.
74. 74 Grassian, A.R., et al. Isocitrate dehydrogenase (IDH) mutations promote a reversible ZEB1/microRNA (miR)-200-dependent epithelial–mesenchymal transition (EMT). J. Biol. Chem. 287 (2012), 42180–42194.
75. 75 Brandes, A.A., et al. A phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma. Neuro. Oncol. 18 (2016), 1146–1156.
76. 76 Melisi, D., et al. A phase II, double-blind study of galunisertib + gemcitabine (GG) vs gemcitabine + placebo (GP) in patients (pts) with unresectable pancreatic cancer (PC). J. Clin. Oncol., 34(Suppl), 2016, A4019.
77. 77 Faivre, S.J., A phase 2 study of galunisertib, a novel transforming growth factor-beta (TGF-β) receptor I kinase inhibitor, in patients with advanced hepatocellular carcinoma (HCC) and low serum alpha fetoprotein (AFP). J. Clin. Oncol., 34(Suppl), 2016, A4070.
78. 78 Brunen, D., et al. TGF-β: an emerging player in drug resistance. Cell Cycle 12 (2013), 2960–2968.
79. 79 Huang, S., et al. MED12 controls the response to multiple cancer drugs through regulation of TGF-β receptor signaling. Cell 151 (2012), 937–950.
80. 80 Sun, C., et al. Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma. Nature 508 (2014), 118–122.
81. 81 Bhola, N.E., et al. TGF-β inhibition enhances chemotherapy action against triple-negative breast cancer. J. Clin. Invest. 123 (2013), 1348–1358.
82. 82 Serova, M., et al. Effects of TGF-β signalling inhibition with galunisertib (LY2157299) in hepatocellular carcinoma models and in ex vivo whole tumor tissue samples from patients. Oncotarget 6 (2015), 21614–21627.
83. 83 Serizawa, M., et al. Combined treatment with erlotinib and a transforming growth factor-β type I receptor inhibitor effectively suppresses the enhanced motility of erlotinib-resistant non-small-cell lung cancer cells. J. Thorac. Oncol. 8 (2013), 259–269.
84. 84 Colak, S., Medema, J.P., Cancer stem cells – important players in tumor therapy resistance. FEBS J. 281 (2014), 4779–4791.
85. 85 Colak, S., et al. Decreased mitochondrial priming determines chemoresistance of colon cancer stem cells. Cell Death Differ. 21 (2014), 1170–1177.
86. 86 Mani, S.A., et al. The epithelial–mesenchymal transition generates cells with properties of stem cells. Cell 133 (2008), 704–715.
87. high glioma-initiating cell population in human glioblastoma. Cancer Cell 18 (2010), 655–668.
88. 88 Hardee, M.E., et al. Resistance of glioblastoma-initiating cells to radiation mediated by the tumor microenvironment can be abolished by inhibiting transforming growth factor-β. Cancer Res. 72 (2012), 4119–4129.
89. 89 Panis, C., et al. Screening of circulating TGF-β levels and its clinicopathological significance in human breast cancer. Anticancer Res. 33 (2013), 737–742.
90. 90 Loh, J.K., et al. Plasma levels of transforming growth factor-β1 before and after removal of low- and high-grade astrocytomas. Cytokine 61 (2013), 413–418.
91. 91 Lin, T.H., et al. High serum transforming growth factor-β1 levels predict outcome in hepatocellular carcinoma patients treated with Sorafenib. Clin. Cancer Res. 21 (2015), 3678–3684.
92. 92 Padua, D., et al. TGFβ primes breast tumors for lung metastasis seeding through angiopoietin-like 4. Cell 133 (2008), 66–77.
93. 93 Bierie, B., et al. Abrogation of TGF-β signaling enhances chemokine production and correlates with prognosis in human breast cancer. J. Clin. Invest. 119 (2009), 1571–1582.
94. 94 Coulouarn, C., et al. Transforming growth factor-β gene expression signature in mouse hepatocytes predicts clinical outcome in human cancer. Hepatology 47 (2008), 2059–2067.
95. 95 Tauriello, D.V., Batlle, E., Targeting the microenvironment in advanced colorectal cancer. Trends Cancer 2 (2016), 495–504.
96. 96 Fessler, E., et al. TGFβ signaling directs serrated adenomas to the mesenchymal colorectal cancer subtype. EMBO Mol. Med. 8 (2016), 745–760.
97. 97 Fessler, E., Medema, J.P., Colorectal cancer subtypes: developmental origin and microenvironmental regulation. Trends Cancer 2 (2016), 505–518.
98. 98 Liu, Q., et al. Genetic, epigenetic, and molecular landscapes of multifocal and multicentric glioblastoma. Acta. Neuropathol. 130 (2015), 587–597.
99. 99 Collisson, E.A., et al. Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Nat. Med. 17 (2011), 500–503.
100. 100 Lehmann, B.D., et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J. Clin. Invest. 121 (2011), 2750–2767.
101. 101 Yang, D., et al. Integrated analyses identify a master microRNA regulatory network for the mesenchymal subtype in serous ovarian cancer. Cancer Cell 23 (2013), 186–199.
102. 102 Kim, H.S., et al. Systematic identification of molecular subtype-selective vulnerabilities in non-small-cell lung cancer. Cell 155 (2013), 552–566.
103. 103 Eichhorn, P.J., et al. USP15 stabilizes TGF-β receptor I and promotes oncogenesis through the activation of TGF-β signaling in glioblastoma. Nat. Med. 18 (2012), 429–435.
104. 104 Bruna, A., et al. High TGFβ–Smad activity confers poor prognosis in glioma patients and promotes cell proliferation depending on the methylation of the PDGF-B gene. Cancer Cell 11 (2007), 147–160.
105. 105 de Kruijf, E.M., et al. The prognostic role of TGF-β signaling pathway in breast cancer patients. Ann. Oncol. 24 (2013), 384–390.
106. 106 Alix-Panabieres, C., Pantel, K., Clinical applications of circulating tumor cells and circulating tumor DNA as liquid biopsy. Cancer Discov. 6 (2016), 479–491.
107. 107 Parkinson, D.R., et al. Considerations in the development of circulating tumor cell technology for clinical use. J. Transl. Med., 10, 2012, 138.
108. 108 Diaz, L.A. Jr., Bardelli, A., Liquid biopsies: genotyping circulating tumor DNA. J. Clin. Oncol. 32 (2014), 579–586.
109. 109 Gazzaniga, P., et al. Circulating tumor cells detection has independent prognostic impact in high-risk non-muscle invasive bladder cancer. Int. J. Cancer 135 (2014), 1978–1982.
110. 110 Rack, B., et al. Circulating tumor cells predict survival in early average-to-high risk breast cancer patients. J. Natl. Cancer Inst., 106, 2014, dju066.
111. 111 Schulze, K., et al. Presence of EpCAM-positive circulating tumor cells as biomarker for systemic disease strongly correlates to survival in patients with hepatocellular carcinoma. Int. J. Cancer 133 (2013), 2165–2171.
112. 112 Heitzer, E., et al. Complex tumor genomes inferred from single circulating tumor cells by array-CGH and next-generation sequencing. Cancer Res. 73 (2013), 2965–2975.
113. 113 Yu, M., et al. Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science 339 (2013), 580–584.
114. 114 Schwarzenbach, H., et al. Cell-free nucleic acids as biomarkers in cancer patients. Nat. Rev. Cancer 11 (2011), 426–437.
115. 115 Douillard, J.Y., et al. First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study. Br. J. Cancer 110 (2014), 55–62.
116. 116 Lacouture, M.E., et al. Cutaneous keratoacanthomas/squamous cell carcinomas associated with neutralization of transforming growth factor β by the monoclonal antibody fresolimumab (GC1008). Cancer Immunol. Immunother. 64 (2015), 437–446.